VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PRQR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PRQRProQR Therapeutics N.V.
$1.15$116M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksPRQRFinancials

ProQR Therapeutics N.V. (PRQR) Income Statement

13Y historyFree accessUpdated daily

Revenue has been lumpy, swinging between $2.1M and $8.9M over ten quarters, while R&D of $12.9M in 2026Q2 and a -100.7% operating margin indicate that the cost base remains far too large for the current revenue run-rate.

Income StatementBalance SheetCash FlowRatios

PRQR Income Statement

Annual statement

PRQR Income Statement

ProQR Therapeutics N.V. (PRQR) annual income statement — 13-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Sales/Revenue18.57M15.28M18.91M6.51M3.59M1.33M1.03M1.93M4.94M-1.53M2.28M9.41M313K0
Revenue Growth %12.66%-19.18%190.22%81.25%169.21%29.74%-46.77%-60.88%423.15%-167%-75.74%2905.43%--
Cost of Goods Sold1.42M2.6M00000116.82M983.51K1M1.28M482.85K00
COGS % of Revenue-16.99%-----6043.61%19.91%-65.49%56.16%5.13%--
Gross Profit17.15M12.68M18.91M6.51M3.59M1.33M1.03M-114.89M3.96M-2.53M1M8.92M313K0
Gross Margin %92.33%83.01%100%100%100%100%100%-5943.61%80.09%165.49%43.84%94.87%100%-
Gross Profit Growth %--32.92%190.22%81.25%169.21%29.74%100.9%-3003.1%256.4%-352.93%-88.79%2751.17%--
Operating Expenses60.37M54.84M49.38M38.37M68.75M58.55M43.4M59.38M42.05M41.99M41.4M30.24M16.77M3.24M
OpEx % of Revenue-358.92%261.18%589.09%1912.99%4385.39%4217.4%3071.81%851.12%-2746.44%1814.24%321.44%5359.11%-
Selling, General & Admin15.14M15.06M13.66M16.24M18.65M17.37M13.69M12.89M12.54M10.84M9.48M6.84M6.51M786K
SG&A % of Revenue-98.57%72.26%249.25%518.95%1300.97%1329.93%666.68%253.79%-708.96%415.34%72.68%2078.91%-
Research & Development45.9M40.72M36.36M25.15M50.87M42.22M38.13M46.49M29.51M31.15M31.92M23.4M10.27M2.57M
R&D % of Revenue-266.51%192.31%386.06%1415.33%3162.55%3706.03%2405.12%597.33%-2037.48%1398.9%248.76%3280.19%-
Other Operating Expenses-670.07K-941.13K-640K-3.01M-765K-1.04M-8.42M1.93M5.76M1.5M1.83M3.23M00
Operating Income-43.22M-42.15M-30.47M-31.86M-65.16M-57.21M-42.37M-57.45M-36.29M-40.5M-39.57M-27M-16.46M-3.24M
Operating Margin %-232.71%-275.91%-161.18%-489.09%-1812.99%-4285.39%-4117.4%-2971.81%-734.53%2648.66%-1734.14%-287.05%-5259.11%-
Operating Income Growth %--38.34%4.35%51.11%-13.89%-35.03%26.25%-58.28%10.38%-2.34%-46.55%-64.04%-408.21%-
EBITDA-40.46M-39.45M-27.71M-29.35M-62.64M-54.88M-40.01M-55.39M-35.3M-39.43M-38.33M-26.52M-16.34M-3.21M
EBITDA Margin %-217.84%-258.22%-146.58%-450.51%-1742.85%-4110.94%-3888.54%-2865.65%-714.45%2579.01%-1679.58%-281.95%-5218.85%-
EBITDA Growth %-3.35%-42.37%5.57%53.15%-14.13%-37.16%27.77%-56.92%10.48%-2.88%-44.51%-62.37%-408.09%-
D&A (Non-Cash Add-back)2.76M2.7M2.76M2.51M2.52M2.33M2.35M2.05M992K1.06M1.25M480K126K24K
EBIT-40.46M-39.63M-26.88M-26.61M-58.98M-57.28M-50.79M-172.35M-36.27M0-37.21M36.8M21.37M-3.21M
Net Interest Income697.22K1.37M2.17M1.39M-5.02M-3.4M-1.73M-681K-1.6M-3.77M-68K5.78M4.07M-14K
Interest Income697.22K2.24M3.25M2.59M106K5K313K402K-792K-3.17M470K6.17M4.33M24K
Interest Expense0866.4K1.08M1.2M5.13M3.4M2.04M1.08M810K596K538K395K265K38K
Other Income/Expense847.34K1.65M2.51M4.05M1.05M-3.47M-4.12M117.65M-792K850.31K470K6.17M4.33M-14K
Pretax Income-42.38M-40.5M-27.96M-27.81M-64.11M-60.68M-46.49M-56.61M-37.09M-43.67M-39.1M-20.83M-12.13M-3.25M
Pretax Margin %-228.15%-265.09%-147.9%-426.97%-1783.75%-4545.47%-4517.98%-2928.82%-750.56%2856.31%-1713.54%-221.45%-3874.44%-
Income Tax26.41K18.25K-197K-78K96K117K124K132K1K2K00024K
Effective Tax Rate %-0.06%-0.05%0.7%0.28%-0.15%-0.19%-0.27%-0.23%-0%-0%0%0%0%-0.74%
Net Income-42.4M-40.52M-27.76M-28.12M-64.42M-60.74M-46.56M-56.75M-36.89M-43.64M-39.1M-20.83M-12.13M-3.25M
Net Margin %-228.29%-265.21%-146.86%-431.67%-1792.54%-4549.81%-4525.27%-2935.64%-746.69%2853.96%-1713.54%-221.45%-3874.44%-
Net Income Growth %-6.88%-45.95%1.27%56.35%-6.07%-30.44%17.94%-53.81%15.45%-11.59%-87.71%-71.78%-272.79%-
Net Income (Continuing)-42.4M-40.52M-27.76M-27.73M-64.2M-60.8M-46.61M-56.75M-36.89M-43.64M-39.1M-20.83M-12.13M-3.25M
Discontinued Operations00000000000000
Minority Interest0000-409.82K-686.87K-666.83K-556.76K-262.92K-45.63K0000
EPS (Diluted)-0.39-0.38-0.34-0.35-0.91-0.96-0.93-1.38-1.08-1.72-1.67-0.89-0.55-0.15
EPS Growth %7.8%-11.76%2.86%61.54%5.21%-3.23%32.61%-27.78%37.21%-2.99%-87.64%-61.82%-266.67%-
EPS (Basic)--0.38-0.34-0.35-0.91-0.96-0.93-1.38-1.08-1.72-1.67-0.89-0.55-0.15
Diluted Shares Outstanding109.96M105.33M81.67M81.01M71.64M64.18M50.06M41.04M34.05M25.37M23.35M23.34M22.15M22.21M
Basic Shares Outstanding109.96M105.33M81.67M81.01M71.64M64.18M50.06M41.04M34.05M25.37M23.35M23.34M22.15M22.21M
Dividend Payout Ratio--------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Persistent operating losses dominate

Lumpy Collaboration Revenue Without Clear Compounding

Based on reported quarterly figures, PRQR's revenue swung between $2.1M and $8.9M over ten quarters, with the latest quarter's 133.3% year-over-year jump appearing to reflect irregular licensing or collaboration recognition rather than durable commercial demand.

The revenue series shows no consistent upward trajectory, with several quarters near $3-4M interspersed with sharp spikes. This pattern is typical of milestone-driven biotech income rather than product sales. Investors should monitor whether the 2026Q2 spike recurs, since a single-quarter jump does not establish growth durability.

Gross Margin Reflects Revenue Mix Not Pricing Power

As reported in the income statement, PRQR's gross margin oscillated between 65.9% and 100.0%, with COGS appearing only in 2026 quarters, suggesting a shift in revenue composition rather than a structural change in pricing power.

Gross margin prints of 100% for most of the period reflect the absence of reported cost of goods rather than an efficient cost base. The emergence of COGS in 2026 coincides with the revenue spike, which may indicate a product or service stream with associated direct costs. Peer comparison is limited, as margin profiles across the group vary widely by business model.

R&D Dominates a Persistently Loss-Making Cost Base

Based on the reported income statement, PRQR's R&D expense ran between $7.0M and $12.9M per quarter, consuming well over twice the company's revenue in most periods and driving operating losses throughout the decade.

R&D is the principal cost line, and its level relative to revenue indicates the company remains in a development-stage cost structure. SG&A held relatively steady near $3-5M, implying limited overhead scaling. Whether R&D intensity declines as programs advance is the central question, and the data do not yet show that trend.

Operating Losses Widen Despite Stable Overhead

As reported in financial statements, PRQR's operating loss ranged from $3.6M to $13.9M, and the operating margin remained deeply negative, indicating that the revenue base has not yet scaled to offset a largely fixed development spend.

Operating leverage is currently negative because cost growth in R&D outpaces the irregular revenue line. The most recent quarter shows operating loss of $9.0M against $8.9M of revenue, reflecting how little of the cost base revenue currently covers. Positive operating leverage would require revenue to become recurring at a scale that absorbs R&D.

Net Loss Tracks Operations with Minimal Adjustments

Based on reported figures, PRQR's net loss closely tracks operating loss, with EPS of -$0.08 to -$0.13 and stock-based compensation of $0.6M to $1.4M per quarter, suggesting limited non-operating distortion in reported earnings.

Net income sits close to operating income in most quarters, indicating few material non-operating items affecting the bottom line. Stock-based compensation rose in 2026 to $1.4M, which warrants monitoring as it adds to economic cost. Earnings quality is less of a concern than the underlying operating loss itself.

Revenue Spike May Not Survive Scrutiny

Based on reported figures, the 2026Q2 revenue of $8.9M against a $2.1M prior quarter may prove non-recurring, and a bear case would argue that operating losses of $9.0M persist regardless of the headline jump.

Short-side analysis would focus on whether the latest revenue spike reflects one-time milestone recognition rather than sustainable demand, since the prior eight quarters averaged well below this level. Even with the spike, operating expenses of roughly $12.9M in R&D alone imply that a single strong quarter does not close the funding gap. Investors should monitor whether subsequent quarters sustain revenue near this level before extrapolating growth.

PRQR — Frequently Asked Questions

Quick answers to the most common questions about buying PRQR stock.

What was ProQR Therapeutics N.V.'s (PRQR) revenue in 2025?

For fiscal year 2025, ProQR Therapeutics N.V. (PRQR) reported total revenue of $15.3M.

Is ProQR Therapeutics N.V. (PRQR) profitable?

ProQR Therapeutics N.V. (PRQR) reported a net loss of $40.5M for the fiscal year ending 2025.

What is ProQR Therapeutics N.V.'s operating profit margin?

ProQR Therapeutics N.V. (PRQR) reported an operating income of $-42.2M, resulting in an operating profit margin of -275.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is ProQR Therapeutics N.V.'s gross profit and gross margin?

ProQR Therapeutics N.V. (PRQR) generated $12.7M in gross profit for the year, representing a gross profit margin of 83.0%. This demonstrates the company's core pricing power and production efficiency.